We identified a conserved function of activated SUMOylation in protecting tumor cells against immune destruction, which is further reinforced by a recent genome-wide screening for MHC-I regulators in DLBCL that also identified SUMO2 as a candidate negative MHC-I regulator (48). The gene discussed is SUMO2; the disease is neoplasm.